July 2022 Top Biopharma Deal: Orion – MSD for Prostate Cancer Drug ODM-208
July 2022 Top Biopharma Deal Upfront
Orion co-development and co-commercialization deal with MSD for ODM-208
Highlighted Deal Financial Comps
Date Announced:
July 13, 2022
Total Deal Value:
$290M + Undisclosed milestones
Upfront Cash:
$290M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
Undisclosed dev., reg., and sales milestones
Royalties:
Undisclosed, tiered, double-digit
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Orion’s ODM-208, non-steroidal, selective CYP11A1 enzyme inhibitor for prostate cancer
Deal Structure:
Development and Commercial License
Partnership Features:
Co-Development and Co-Promotion, Shared Promotion Cost; Supply by Licensor
Deal Details:
- Orion granted MSD exclusive, worldwide rights to co-develop and co-commercialize ODM-208 for the treatment of metastatic castration-resistant prostate cancer.
- Orion and MSD have an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to MSD. Upon exercising the option, MSD will retain the responsibility for all accrued and future development and commercialization expenses associated with the program.
- Orion will receive $290M up front including $221M recognized as income, and approximately $60.3M reserved to cover Orion’s share of the ODM-208 future development cost. Orion is eligible for undisclosed development and commercialization milestones, plus tiered double-digit royalties.
Last Month:
Congrats to Orion and MSD for landing DealForma’s July 2022 Top Biopharma Deal. Last month’s Deal of the Month was Sanofi – Regeneron Pharmaceuticals for cancer/inflammation drug Libtayo. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...